Clinical Trial Update: Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

An update on a dose-escalation Phase 1/2 trial of Opexa's autologous T cell vaccine for relapsing-remitting and secondary progressive multiple sclerosis, which …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tovaxin

Snippet

Sponsor: Opexa Therapeutics, Inc. | Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1, Phase 2 | Status: COMPLETED